MorphoSys AG's Antibodies By Design And JPT Peptide Technologies GmbH Announce Cooperation Agreement 
10/19/2005 5:13:04 PM

BERLIN & MARTINSRIED/MUNICH, Germany--(BUSINESS WIRE)--April 18, 2005--Antibodies by Design, a division of MorphoSys AG and JPT Peptide Technologies GmbH, a wholly-owned subsidiary of Jerini AG, today announced the start of a co-marketing agreement between the two specialist companies. Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other to its customers throughout the world-wide market, with exception of Japan. "We are very glad to have reached an agreement with JPT which bears enormous advantages for both companies, and also for our customers", stated Dieter Lingelbach, Head of the Antibodies by Design division and Senior Vice President of MorphoSys AG. "Both companies are absolute specialists in their field and belong to the top addresses for antibody development and innovative peptide-based services in Europe."